Aortic Stenosis

Aortic Stenosis – High‑Yield Study Guide for Medical Students

Definition

Aortic stenosis (AS) is a valvular heart disease characterized by progressive narrowing and obstruction of blood flow across the aortic valve, leading to increased left ventricular (LV) pressure overload, concentric hypertrophy, and eventually LV systolic dysfunction and heart failure.

Clinically, severity is graded by echocardiographic parameters, typically using aortic valve area (AVA), mean transvalvular gradient, and peak velocity:

• Mild: AVA > 1.5 cm², mean gradient < 20 mmHg
• Moderate: AVA 1.0–1.5 cm², mean gradient 20–39 mmHg
• Severe: AVA ≤ 1.0 cm², mean gradient ≥ 40 mmHg, peak velocity ≥ 4.0 m/s

Epidemiology

Aortic stenosis is the most common valvular lesion in adults in high‑income countries and a major indication for valve intervention. Degenerative calcific AS is primarily a disease of aging, with prevalence increasing notably in patients > 65 years. Bicuspid aortic valve, present in 1–2% of the population, is an important cause of AS in younger adults and accelerates disease progression. Population‑level data show that moderate to severe AS confers high untreated mortality, underlining the importance of timely recognition and intervention. [9](https://europepmc.org/article/MED/41815106)

Pathophysiology

The pathophysiology of aortic stenosis involves chronic progressive obstruction to LV outflow resulting from leaflet thickening, calcification, or congenital malformation.

• Valve level: In degenerative calcific AS, repetitive mechanical stress at the leaflet tips triggers inflammation, lipid deposition, and active calcific remodeling, ultimately restricting leaflet excursion and narrowing the valve orifice.
• Pressure overload: LV must generate higher systolic pressure to maintain forward stroke volume, resulting in concentric LV hypertrophy that initially preserves ejection fraction but increases diastolic stiffness and myocardial oxygen demand.
• Myocardial damage: Chronic pressure overload leads to myocyte hypertrophy, interstitial fibrosis, microvascular dysfunction, and eventually LV systolic impairment and heart failure if obstruction is not relieved.
• Downstream effects: Progressive AS can cause elevated LV end‑diastolic pressure, pulmonary venous hypertension, pulmonary hypertension, right ventricular dysfunction, and secondary tricuspid regurgitation; such advanced cardiac damage has been shown to worsen short‑ and mid‑term mortality and rehospitalization after transcatheter aortic valve implantation (TAVI). [8](https://europepmc.org/article/MED/41791868)

Etiology and Risk Factors

Common causes of aortic stenosis include:

• Degenerative calcific disease: Most common in older adults, often associated with traditional atherosclerotic risk factors (age, hypertension, hyperlipidemia, smoking).
• Bicuspid aortic valve (BAV): Congenital two‑leaflet valve with increased mechanical stress and accelerated calcification; may coexist with aortopathy.
• Rheumatic heart disease: Commissural fusion and thickening, often with concomitant mitral valve involvement, still relevant in low‑ and middle‑income settings.
• Radiation‑induced valvulopathy: Late complication of mediastinal radiation.
• Other rare causes: Subvalvular or supravalvular stenosis, storage diseases (e.g., Fabry), and end‑stage chronic kidney disease with accelerated calcification.

Clinical Presentation

Many patients remain asymptomatic for years despite severe obstruction; symptom onset typically marks a turning point with significantly increased mortality without intervention.

Classic symptoms

• Exertional dyspnea: From elevated LV filling pressures and secondary pulmonary congestion; may present as reduced exercise tolerance.
• Angina: Imbalance between increased myocardial oxygen demand (due to hypertrophy) and reduced supply, even in absence of epicardial CAD.
• Syncope or presyncope: Often exertional, related to fixed stroke volume, vasodilation during exercise, and sometimes arrhythmias.
• Heart failure symptoms: Orthopnea, PND, peripheral edema in late disease.

Physical examination

• Murmur: Harsh, crescendo‑decrescendo systolic ejection murmur best heard at right second intercostal space, radiating to carotids; intensity often correlates with gradient but may soften with LV dysfunction.
• S1/S2: Soft or absent A2 (single S2) in severe AS; an ejection click may be heard in younger patients with pliable congenital or bicuspid valves.
• Pulses: Slow‑rising, low‑amplitude carotid pulse (pulsus parvus et tardus) in classic severe AS.
• Heave: Sustained, forceful LV apical impulse due to hypertrophy.
• Signs of advanced disease: Elevated JVP, pulmonary rales, hepatomegaly, peripheral edema.

Diagnostic Evaluation

Diagnosis and grading of aortic stenosis rely primarily on transthoracic echocardiography, integrated with clinical findings and, when needed, additional imaging and hemodynamic assessment.

Initial assessment

• History and exam: Clarify exertional symptoms, syncope, angina, heart failure signs, and comorbidities.
• Electrocardiogram: LV hypertrophy with strain, left atrial enlargement, conduction abnormalities, or arrhythmias.
• Chest X‑ray: Post‑stenotic aortic dilatation, calcified valve, LV enlargement, pulmonary congestion in advanced disease.

Echocardiography

Transthoracic echocardiography (TTE) is the gold‑standard noninvasive test for diagnosis, quantification, and serial follow‑up of AS, and it is central to modern guideline‑directed decision making. [1](https://pubmed.ncbi.nlm.nih.gov/41841672)

• Parameters:
  • Peak jet velocity across the aortic valve
  • Mean transvalvular gradient
  • Aortic valve area (continuity equation)
  • LV ejection fraction, LV mass and size
  • Assessment of other valves, pulmonary pressures, and aorta
• Severity grading: Uses integrated assessment of AVA, gradients, and flow; attention to low‑flow, low‑gradient AS phenotypes (reduced vs preserved EF).

Additional diagnostic tools

• Stress echocardiography: Dobutamine stress echo helps differentiate true severe from pseudo‑severe low‑flow, low‑gradient AS with reduced EF by assessing contractile reserve and gradient changes.
• Cardiac CT: Useful for quantifying aortic valve calcium burden, particularly in ambiguous cases, and essential for annular sizing, coronary ostial height, and access planning before transcatheter aortic valve replacement (TAVR). [5](https://pubmed.ncbi.nlm.nih.gov/41827334)
• Cardiac catheterization: Reserved for situations where noninvasive measurements are inconclusive or to evaluate coronary anatomy prior to surgical or transcatheter intervention.
• Risk stratification: Clinical risk scores incorporating routine electronic health record data can predict progression and 3‑year risk of AS events, potentially assisting in identifying patients who would benefit from closer monitoring. [9](https://europepmc.org/article/MED/41815106)

Severity Classification and Natural History

AS typically progresses from asymptomatic to symptomatic severe disease with a marked change in prognosis when classic symptoms appear. Untreated severe symptomatic AS is associated with poor outcomes, while timely intervention restores survival to near age‑matched controls in many patients.

• Asymptomatic severe AS: Often monitored with serial echocardiography; intervention considered if LV dysfunction, very high gradient/velocity, abnormal exercise test, or rapid progression.
• Moderate AS: Carries significant risk for cardiac death and HF hospitalization over time; evolving data and clinical risk scores highlight the need for individualized follow‑up and reconsideration of timing of intervention in certain high‑risk subsets. [7](https://europepmc.org/article/MED/41834049)
• Symptomatic severe AS: Generally warrants prompt valve intervention (surgical AVR or TAVR) after heart team evaluation. [1](https://pubmed.ncbi.nlm.nih.gov/41841672)

Management

Management of aortic stenosis is guided by symptom status, AS severity, LV function, comorbidities, and anticipated life expectancy. The mainstay of treatment is valve replacement; no medical therapy has been shown to halt progression of valvular obstruction.

General and medical management

• Risk factor modification: Address hypertension, diabetes, dyslipidemia, and smoking to reduce global cardiovascular risk, although these do not reverse AS.
• Blood pressure: Carefully treat hypertension; avoid excessive afterload reduction that could compromise coronary perfusion or systemic pressure in advanced AS.
• Heart failure management: Diuretics may be used cautiously for congestion; avoid aggressive preload reduction in severe AS due to fixed stroke volume.
• Activity: Restrict strenuous exertion and competitive sports in severe symptomatic AS; asymptomatic severe disease requires individualized advice based on exercise testing and echocardiographic data.

Definitive intervention: Aortic valve replacement

Valve intervention is recommended for symptomatic severe AS or asymptomatic severe AS with LV systolic dysfunction or high‑risk features. The 2025 ESC/EACTS valvular disease guidelines emphasize individualized decision‑making regarding timing and modality of intervention, integrating patient age, comorbidities, anatomy, and lifetime management perspective. [1](https://pubmed.ncbi.nlm.nih.gov/41841672) [5](https://pubmed.ncbi.nlm.nih.gov/41827334)

Surgical aortic valve replacement (SAVR)

• Indications: Symptomatic severe AS in patients at low surgical risk and acceptable operative profile; also preferred in cases with concomitant coronary bypass or other valve surgery requirements.
• Valve choice:
  • Mechanical valves: Durable, indicated in younger patients willing to take lifelong anticoagulation.
  • Bioprosthetic valves: Used more commonly in older patients; avoid prolonged anticoagulation but have limited durability.

Transcatheter aortic valve replacement (TAVR/TAVI)

TAVR has transformed AS management and is now used across a broad risk spectrum, particularly in older or higher‑risk patients. Contemporary guidance stresses planning within a lifetime management strategy, anticipating future reinterventions. [5](https://pubmed.ncbi.nlm.nih.gov/41827334)

• Indications: Classically for severe symptomatic AS in patients with intermediate or high surgical risk, but increasingly considered even in lower‑risk older patients after Heart Team evaluation.
• Access routes: Primarily transfemoral; alternatives (transapical, transaxillary, transcarotid) when femoral access unsuitable.
• Valve types:
  • Self‑expanding valves: Often associated with larger effective orifice area and lower risk of prosthesis–patient mismatch, which may be particularly advantageous in patients with small aortic annulus. [3](https://pubmed.ncbi.nlm.nih.gov/41836204) [6](https://europepmc.org/article/PMC/PMC12980094)
  • Balloon‑expandable valves: Offer precise positioning; selection is influenced by annular size, calcium distribution, and coronary anatomy.
• Advanced cardiac damage: Presence of right ventricular dysfunction, pulmonary hypertension, or significant tricuspid regurgitation prior to TAVR is associated with increased mortality and rehospitalization, reinforcing the value of earlier intervention before extensive cardiac remodeling. [8](https://europepmc.org/article/MED/41791868)
• Lifetime management: Planning for valve‑in‑valve TAVR, possible future surgical explant, and coronary access is critical, especially in younger patients. [5](https://pubmed.ncbi.nlm.nih.gov/41827334)

Special scenarios

• Low‑flow, low‑gradient severe AS: Requires careful evaluation with echocardiography, dobutamine stress, and CT calcium scoring to confirm severity and guide AVR/TAVR decisions.
• Multivalvular disease: In patients with concomitant severe AS and moderate/severe mitral stenosis, double valve surgery may reduce heart failure readmissions compared with isolated TAVR, suggesting that surgical double‑valve approaches remain important in selected high‑grade multivalvular pathology. [10](https://europepmc.org/article/MED/41729877)
• Valve thrombosis post‑TAVR: Subclinical leaflet thrombosis and clinically overt TAVR valve thrombosis can impair valve hemodynamics and longevity; understanding risk factors, surveillance imaging, and antithrombotic strategies is essential in lifetime management. [4](https://pubmed.ncbi.nlm.nih.gov/41834772) [5](https://pubmed.ncbi.nlm.nih.gov/41827334)

Complications

• Heart failure: Both preserved and reduced EF phenotypes; decompensation often signals need for urgent intervention.
• Arrhythmias: Atrial fibrillation (from left atrial enlargement), ventricular arrhythmias, and conduction system disease (especially post‑TAVR).
• Sudden cardiac death: Higher risk in symptomatic severe AS and in those with LV dysfunction or complex arrhythmias.
• Infective endocarditis: Risk is increased in prosthetic valves (SAVR and TAVR) and requires prophylaxis according to guideline indications.
• Post‑intervention complications: Paravalvular leak, prosthesis–patient mismatch (more frequent in small annulus with certain prostheses), valve thrombosis, and structural valve degeneration over time. [3](https://pubmed.ncbi.nlm.nih.gov/41836204) [4](https://pubmed.ncbi.nlm.nih.gov/41834772) [5](https://pubmed.ncbi.nlm.nih.gov/41827334)

Key Clinical Pearls for Exams and Practice

• Classic triad: Exertional dyspnea, angina, and syncope in a patient with a harsh systolic ejection murmur radiating to the carotids is high‑yield for AS.
• Murmur timing: Crescendo–decrescendo systolic murmur at the right upper sternal border that peaks later in systole as AS becomes more severe.
• Asymptomatic phase: Patients can have severe AS without symptoms; look for red flags (LV dysfunction, very high jet velocity, abnormal exercise test) to time surgery before irreversible damage.
• Fixed afterload concept: In severe AS, the LV sees a fixed obstruction; be cautious with vasodilators and aggressive diuresis, particularly in hypotensive patients.
• Echocardiography is central: Always correlate AVA, gradients, and flow; be wary of low‑flow, low‑gradient phenotypes and use stress echo or CT calcium score when unsure.
• TAVR vs SAVR: Modern ESC/EACTS guidelines emphasize Heart Team–based selection and lifetime management perspective, including future reinterventions. [1](https://pubmed.ncbi.nlm.nih.gov/41841672) [5](https://pubmed.ncbi.nlm.nih.gov/41827334)
• Small annulus issues: Self‑expanding TAVR valves may have hemodynamic advantages (larger effective orifice area, lower gradients) in small annulus patients, potentially reducing prosthesis–patient mismatch. [3](https://pubmed.ncbi.nlm.nih.gov/41836204) [6](https://europepmc.org/article/PMC/PMC12980094)
• Advanced cardiac damage: Presence of RV dysfunction, pulmonary hypertension, or severe TR in severe AS predicts worse outcomes after TAVR, supporting earlier referral before extensive remodeling. [8](https://europepmc.org/article/MED/41791868)
• Moderate AS is not benign: Emerging data and risk scores highlight substantial risk of HF hospitalization and cardiac death, prompting close surveillance and possible earlier intervention in selected patients. [7](https://europepmc.org/article/MED/41834049) [9](https://europepmc.org/article/MED/41815106)

Summary

Aortic stenosis is a progressive, often degenerative valvular disease characterized by LV pressure overload and concentric hypertrophy. Diagnosis centers on echocardiography, and prognosis dramatically worsens after symptom onset. Contemporary guidelines and the expanding role of TAVR demand a lifetime management perspective, integrating patient‑specific anatomy, comorbidities, and future reintervention strategies. Understanding the clinical presentation, echo criteria, and indications for SAVR versus TAVR is essential for medical students preparing for examinations and for clinical practice. [1](https://pubmed.ncbi.nlm.nih.gov/41841672) [5](https://pubmed.ncbi.nlm.nih.gov/41827334)